Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organ Preservation With Short-Course Radiotherapy, CAPOX, and Sintilimab in Early Low Rectal pMMR Cancer
ChiCTR2500113784Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, capecitabine and oxaliplatin in rectal adenocarcinoma and rectal cancer, sponsored by Sun Yat-sen University. Primary endpoint: Rate of clinical complete response and successful local resection (cCR + ypT0-1). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sintilimabcapecitabineoxaliplatin
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ChiCTR2500113784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113784.